HamadaY, NishijimaT, WatanabeK, et al.: High incidence of renal stones among HIV infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor–containing antiretroviral therapy. Clin Infect Dis, 2012; 55:1262–1269.
2.
de LastoursV, Ferrari Rafael De SilvaE, DaudonM, et al.: High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother, 2013; 68:1850–1856.
3.
D'AvolioA, BaiettoL, SiccardiM, et al.: An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit, 2008; 30:662–669.
4.
AndersonPL, LichtensteinKA, GerigNE, et al.: Atazanavir-containing renal calculi in an HIV-infected patient. AIDS, 2007; 21:1060–1062.
5.
Chan-TackKM, TruffaMM, StrubleKA, et al.: Atazanavir-associated nephrolithiasis: Cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS, 2007; 21:1215–1218.
6.
CouzigouC, DaudonM, MeynardJL, et al.: Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis, 2007; 45:e105–e108.
7.
FerrarisL, ViganòO, PeriA, et al.: Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers. J Antimicrob Chemother, 2012; 67:2236–2242.
8.
RockwoodN, MandaliaS, BowerM, et al.: Ritonavir boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS, 2011; 25:1671–1673.
9.
BurgerD, HugenP, ReissP, et al.: Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS, 2003; 17:1157–1165.
10.
LanzafameM, LattuadaE, RigoF, et al.: A maintenance dose of atazanavir/ritonavir 200/100 mg once daily is effective in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr, 2013; 63:e81–82.
